Erbes T, Stickeler E, Rücker G, et al. BMI and Pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer. 2016;8209(16):30048-30049. Li XB, Krishnamurti U, Bhattara...
尽管如此,我们需要MATTERHORN和DANTE的生存结果,然后才能确定pCR作为食管胃癌生存的预测因子的未来。 参考来源 https://dailynews.ascopubs.org/do/pathologic-complete-response-best-surrogate-endpoint-survival-esophagogastric-cancer (来源:肿瘤瞭望-消化时讯) 声明 凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、...
在既往NSCLC的治疗中,传统化疗方案往往pCR率较低,约为4%,因此pCR在新辅助化疗相关研究中应用有限[2]。2012年,一项研究对新辅助化疗后早期NSCLC患者pCR是否会与预后改善相关进行了分析,492例患者中,41例(8.3%)患者达pCR,达pCR的患者...
PURPOSE: Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate for event-free survival (EFS) and overall survival (OS) in human epidermal growth factor receptor 2 (HER2)-positive, early br...
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S. Pathologic complete response and survival in HER2...
Importance: A pathologic complete response (pCR; no invasive or in situ cancer) occurs in 40% to 50% of patients with HER2-positive (HER2+) and triple-negative (TN) breast cancer. The need for surgery if percutaneous biopsy of the breast after neoadjuvant chemotherapy (NCT) indicates pCR in...
IMPORTANCE: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. OBJECTIVE: To evaluate the association of pCR with event...
原文出处:Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权...
瘤医院收治的局部晚期中㊁低位直肠癌经新辅助治疗后原发肿瘤达pCR的52例患者的临床资料,患 者术前临床分期为Ⅱ期(cT3 4N0期)10例,Ⅲ期(cT3 4N+期)42例㊂新辅助治疗后,临床完全缓 解(cCR)10例(19.2%)㊂结果㊀51例患者接受根治性手术,其中5例(9....
参考文献: Effect of pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response inWomen With Early-Stage Breast Cancer. JAMA Oncol. 2020